---
title: "Victory | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 435.36 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295019633.md"
datetime: "2026-08-05T21:32:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295019633.md)
  - [en](https://longbridge.com/en/news/295019633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295019633.md)
generator: "portal-rs"
---

# Victory | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 435.36 M

Revenue: As of FY2026 Q2, the actual value is USD 435.36 M, beating the estimate of USD 386.09 M.

EPS: As of FY2026 Q2, the actual value is USD 1.68, beating the estimate of USD 1.6.

EBIT: As of FY2026 Q2, the actual value is USD 199.44 M.

The provided reference, an 8-K filing by Victory Capital Holdings, Inc., indicates that the actual financial and operational metrics, cash flow data, unique metrics, and outlook/guidance are contained within Exhibit 99.1 (the Earnings Press Release). However, Exhibit 99.1 is not included in the provided text for analysis. Therefore, no specific financial or operational metrics, cash flow data, unique metrics, or outlook/guidance can be extracted from the given content.

### Related Stocks

- [VCTR.US](https://longbridge.com/en/quote/VCTR.US.md)

## Related News & Research

- [Victory Capital Reports August 2026 Total Client Assets | VCTR Stock News](https://longbridge.com/en/news/298728554.md)
- [Victory Capital to acquire First Eagle in cash-and-stock deal](https://longbridge.com/en/news/297560835.md)
- [Vivos Therapeutics amends 8-K to correct report date to Sept. 2, 2026](https://longbridge.com/en/news/298368513.md)
- [BioRestorative amends 8-K to clarify auditor change, audit committee probe scope](https://longbridge.com/en/news/298641440.md)
- [REG - General Elec. - Doc re. GE Files 8-K](https://longbridge.com/en/news/298321667.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**